October 9, 2023 12:58 PM EDT
Pharma
Manufacturing

Bio­con’s in­sulin biosim­i­lar re­ject­ed yet again by FDA af­ter man­u­fac­tur­ing de­fi­cien­cies

Ayisha Sharma

News Reporter

The FDA has re­ject­ed Bio­con Bi­o­log­ics’ biosim­i­lar ver­sion of in­sulin as­part due to is­sues iden­ti­fied at its Malaysia fa­cil­i­ty af­ter an Aug. 2022 in­spec­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Mer­ck KGaA eyes more man­u­fac­tur­ing M&A as it faces head­winds in Chi­na

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times